Prostate-specific membrane antigen inhibitor, radiolabeled derivative, and use thereof

TW202637114APending Publication Date: 2026-09-16CHANGCHUN GENESCIENCE PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114149012
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-10-23
Filing Date
2025-12-12
Publication Date
2026-09-16

Smart Images

  • Figure TWG2TA001076745_001
    Figure TWG2TA001076745_001
  • Figure TWG2TA001076745_002
    Figure TWG2TA001076745_002
  • Figure TWG2TA001076745_003
    Figure TWG2TA001076745_003
Patent Text Reader

Abstract

The present disclosure provides a structurally novel compound targeting PSMA as shown in formula (I), racemate, stereoisomer, tautomer, solvate, polymorphic form, pharmaceutically acceptable salt or prodrug compound, and radioactive isotope label thereof. The compound and its radioactive isotope markers can be widely used in the diagnosis, staging, treatment, or efficacy evaluation of prostate cancer.
Need to check novelty before this filing date? Find Prior Art